MCID: DSS008
MIFTS: 66

Disease of Mental Health

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Disease of Mental Health

Summaries for Disease of Mental Health

MedlinePlus : 43 What is mental health? Mental health includes our emotional, psychological, and social well-being. It affects how we think, feel, and act as we cope with life. It also helps determine how we handle stress, relate to others, and make choices. Mental health is important at every stage of life, from childhood and adolescence through adulthood. What are mental illnesses? Mental illnesses are serious disorders which can affect your thinking, mood, and behavior. They may be occasional or long-lasting. They can affect your ability to relate to others and function each day. Mental disorders are common; more than half of all Americans will be diagnosed with a mental disorder at some time in their life. But there are treatments. People with mental health problems can get better, and many of them recover completely. Why is mental health important? Mental health is important because it can help you to Cope with the stresses of life Be physically healthy Have good relationships Make meaningful contributions to your community Work productively Realize your full potential How can I improve my mental health? There are steps you can take to help you improve your mental health. They include Staying positive Being physically active Connecting with others Developing a sense of meaning and purpose in life Getting enough sleep Developing coping skills Meditating Getting professional help if you need it

MalaCards based summary : Disease of Mental Health, also known as mental disorders, is related to alcohol-induced mental disorder and drug-induced mental disorder, and has symptoms including agitation, lethargy and forgetful. An important gene associated with Disease of Mental Health is BDNF-AS (BDNF Antisense RNA), and among its related pathways/superpathways are Circadian entrainment and Beta-Adrenergic Signaling. The drugs Morphine and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A disease that involves a psychological or behavioral pattern generally associated with subjective distress or disability that occurs in an individual, and which are not a part of normal development or culture.

Wikipedia : 75 Mental health is the level of psychological well-being or an absence of mental illness. It is the state... more...

Related Diseases for Disease of Mental Health

Diseases related to Disease of Mental Health via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 949)
# Related Disease Score Top Affiliating Genes
1 alcohol-induced mental disorder 34.8 SLC6A4 SLC6A3 DRD2
2 drug-induced mental disorder 34.5 HTR2A HTR1A DRD2
3 depression 33.9 SLC6A4 HTR2A HTR1A BDNF-AS BDNF
4 anxiety 33.8 SLC6A4 HTR2A HTR1A COMT BDNF
5 eating disorder 33.8 SLC6A4 SLC6A3 DRD2 COMT BDNF
6 post-traumatic stress disorder 33.7 SLC6A4 HTR2A DRD2 COMT BDNF APOE
7 bipolar disorder 33.7 SLC6A4 SLC6A3 PRODH HTR2A HTR1A DRD3
8 panic disorder 33.5 SLC6A4 HTR2A HTR1A COMT
9 dementia 33.5 SLC6A3 MAPT HTR2A BDNF APOE
10 learning disability 33.5 MECP2 MAPT FMR1
11 obsessive-compulsive disorder 33.5 SLC6A4 SLC6A3 HTR2A HTR1A DRD4 DRD3
12 pervasive developmental disorder 33.5 SLC6A4 MECP2 FMR1 BDNF
13 fibromyalgia 33.5 SLC6A4 HTR2A COMT
14 schizoaffective disorder 33.4 SLC6A4 PRODH HTR2A DRD3 DRD2 COMT
15 major depressive disorder 33.3 SLC6A4 SLC6A3 HTR2A HTR1A HCRT DRD4
16 specific developmental disorder 33.1 SLC6A4 SLC6A3 OPRM1 MECP2 FMR1 DRD4
17 schizophrenia 33.1 SLC6A4 SLC6A3 PRODH MECP2 HTR2A HTR1A
18 sexual disorder 33.1 SLC6A4 PDE5A HTR1A
19 alcoholic psychosis 33.1 SLC6A4 SLC6A3 HTR2A DRD2
20 attention deficit-hyperactivity disorder 33.1 SLC6A4 SLC6A3 OPRM1 MECP2 HTR2A HTR1A
21 impulse control disorder 33.0 DRD4 DRD3 DRD2
22 hypoactive sexual desire disorder 32.9 HTR2A HTR1A
23 substance abuse 32.9 SLC6A4 SLC6A3 DRD4 DRD3 DRD2 COMT
24 mental depression 32.8 SLC6A4 HTR2A HTR1A COMT BDNF
25 personality disorder 32.8 SLC6A4 SLC6A3 HTR2A HTR1A DRD4 DRD2
26 dementia, lewy body 32.7 SLC6A3 MAPT APOE
27 mood disorder 32.5 SLC6A4 HTR2A HTR1A DRD4 DRD3 DRD2
28 postpartum depression 32.5 SLC6A4 COMT BDNF
29 generalized anxiety disorder 32.4 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
30 traumatic brain injury 32.4 DRD2 COMT BDNF APOE
31 conduct disorder 32.3 SLC6A4 SLC6A3 DRD4 DRD2 COMT
32 autism spectrum disorder 32.3 SLC6A4 MECP2 HTR2A FMR1 BDNF
33 social phobia 32.3 SLC6A4 HTR1A DRD2
34 autism 32.3 SLC6A4 MECP2 HTR2A HTR1A FMR1 BDNF
35 psychotic disorder 32.2 SLC6A4 SLC6A3 PRODH HTR2A HTR1A DRD4
36 borderline personality disorder 32.2 SLC6A4 HTR2A HTR1A COMT BDNF
37 brain injury 32.2 MAPT DRD2 COMT BDNF APOE
38 alcohol dependence 32.1 SLC6A4 SLC6A3 OPRM1 HTR2A HTR1A DRD4
39 drug dependence 32.0 SLC6A4 OPRM1 DRD3 DRD2 BDNF
40 oppositional defiant disorder 32.0 SLC6A4 SLC6A3 DRD4 DRD2 COMT
41 tobacco addiction 32.0 SLC6A4 SLC6A3 OPRM1 HTR2A DRD2 COMT
42 antisocial personality disorder 32.0 SLC6A4 SLC6A3 DRD2 COMT
43 substance dependence 31.9 SLC6A4 SLC6A3 OPRM1 DRD4 DRD3 DRD2
44 endogenous depression 31.8 SLC6A4 HTR2A HTR1A BDNF
45 anorexia nervosa 31.8 SLC6A4 HTR2A HCRT COMT BDNF
46 bulimia nervosa 31.7 SLC6A4 HTR2A COMT BDNF
47 pathological gambling 31.7 SLC6A4 SLC6A3 HTR2A DRD4 DRD3 DRD2
48 alexithymia 31.6 SLC6A4 HTR1A DRD2 COMT
49 phobia, specific 31.6 FMR1 COMT
50 chronic fatigue syndrome 31.6 SLC6A4 HTR2A HTR1A COMT

Graphical network of the top 20 diseases related to Disease of Mental Health:



Diseases related to Disease of Mental Health

Symptoms & Phenotypes for Disease of Mental Health

UMLS symptoms related to Disease of Mental Health:


agitation, lethargy, forgetful, decrease in appetite, symptoms, nervousness, feeling jittery, alexithymia, increased libido, numbness, psychiatric symptom, hallucinations, auditory, hallucinations, visual, numbness localized, feeling detached, feeling strange, feeling weightless, floating feeling, dejection emotional, depressed reaction, hallucinations, sensory, restless sleep, difficulty sleeping, excitability, depression aggravated, agitation mental, numb mouth, opiate withdrawal symptoms, clouded consciousness, trembling inside, sluggishness

MGI Mouse Phenotypes related to Disease of Mental Health:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 APOE BDNF COMT DRD2 DRD3 DRD4
2 homeostasis/metabolism MP:0005376 10.21 APOE BDNF COMT DRD2 DRD3 DRD4
3 growth/size/body region MP:0005378 10.18 APOE BDNF DRD2 DRD3 FMR1 HCRT
4 endocrine/exocrine gland MP:0005379 10.13 APOE BDNF COMT DRD2 FMR1 HTR2A
5 cardiovascular system MP:0005385 10.11 APOE COMT DRD2 DRD3 HCRT HTR1A
6 nervous system MP:0003631 10.03 APOE BDNF COMT DRD2 DRD3 DRD4
7 integument MP:0010771 10.02 APOE BDNF DRD2 FMR1 MAPT MECP2
8 muscle MP:0005369 9.8 APOE DRD2 HCRT HTR2A MAPT SLC6A3
9 no phenotypic analysis MP:0003012 9.5 APOE BDNF DRD2 HTR1A MAPT MECP2
10 taste/olfaction MP:0005394 9.02 APOE BDNF DRD2 MAPT SLC6A3

Drugs & Therapeutics for Disease of Mental Health

Drugs for Disease of Mental Health (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 746)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 4 57-27-2 5288826
2
Coal tar Approved Phase 4 8007-45-2
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
6
Ferrous succinate Approved Phase 4 10030-90-7
7
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
8
Methimazole Approved Phase 4 60-56-0 1349907
9
Oxcarbazepine Approved Phase 4 28721-07-5 34312
10
Nifedipine Approved Phase 4 21829-25-4 4485
11
Amlodipine Approved Phase 4 88150-42-9 2162
12
Atenolol Approved Phase 4 29122-68-7 2249
13
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
14
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
15
Amitriptyline Approved Phase 4 50-48-6 2160
16
Clozapine Approved Phase 4 5786-21-0 2818
17
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
18
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
19
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
20
Polyestradiol phosphate Approved Phase 4 28014-46-2
21
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
22
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
23
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
24
Cyproheptadine Approved Phase 4 129-03-3 2913
25
Amisulpride Approved, Investigational Phase 4 53583-79-2, 71675-85-9 2159
26
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
27
Iloperidone Approved Phase 4 133454-47-4 71360
28 Coconut Approved Phase 4
29
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
30
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
31
Perphenazine Approved Phase 4 58-39-9 4748
32
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
33
Cinnarizine Approved, Investigational Phase 4 298-57-7 1547484 2761
34
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
35
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
36
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
37
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
38
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
39
Zolpidem Approved Phase 4 82626-48-0 5732
40
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
41
Pramlintide Approved, Investigational Phase 4 151126-32-8
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
43
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
44
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
45
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
46
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
47
Allantoin Approved Phase 4 97-59-6 204
48
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
49
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
50
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999

Interventional clinical trials:

(show top 50) (show all 5375)
# Name Status NCT ID Phase Drugs
1 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
2 Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic REM Sleep Behavior Disorder: a Pilot Study Unknown status NCT02836743 Phase 4 Circadin;Placebo
3 Randomized, Controlled Study of Iron Supplementation of Infants With Birth Weights 2000-2500 g Unknown status NCT00558454 Phase 4 Iron
4 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
5 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
6 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
7 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
8 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
9 Sequenced Therapies for Comorbid and Primary Insomnias Unknown status NCT01651442 Phase 4 Zolpidem;Trazodone
10 The Effect of a Community-based Long-acting Antipsychotic-treated Management Model on the Violence Risk of Patients With Schizophrenia: a 1-year, Open-label Randomized Controlled Study Unknown status NCT03080194 Phase 4 paliperidone palmitate;control group
11 Cardiopulmonary Capacity In Different Quartiles Ranges Of Reference For Serum Thyroid Stimulating Hormone (TSH): Sectional Evaluation And Effect Of The Use Of Methimazole In Elderly Population Unknown status NCT01849861 Phase 4 Methimazole
12 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
13 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
14 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
15 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
16 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
17 Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
18 The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
19 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
20 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
21 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
22 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
23 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
24 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
25 Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations. Unknown status NCT00708240 Phase 4 Escitalopram
26 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
27 Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study Unknown status NCT02650388 Phase 4
28 A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD) Unknown status NCT02683265 Phase 4 Aptensio XR;Placebo
29 Development of a Nationally Scalable Model of Group Prenatal Care to Improve Birth Outcomes: "Expect With Me" Unknown status NCT02169024 Phase 4
30 Postoperative Pain Relief Following Total Hip Arthroplasty. A Comparison Between Intrathecal Morphine (IM) and Local Infiltration Analgesia (LIA) Unknown status NCT01281891 Phase 4 LIA;I/T morphine
31 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
32 Joining Forces: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana Completed NCT02593734 Phase 4 olanzapine;risperidone;amitryptaline;fluoxetine
33 Randomized Controlled Trial of a Community-based Early Psychiatric Intervention Strategy to Screen and Manage Depression in the Elderly Completed NCT00430404 Phase 4
34 A Randomised Controlled Trial on the Effectiveness of Screening and Brief Counselling for Elderly Patients With Psychological Problems in Primary Care. Completed NCT00283270 Phase 4
35 Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II) Completed NCT02305823 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
36 Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up Completed NCT02526030 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
37 Efficacy and Safety of Paliperidone ER in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study Completed NCT01157585 Phase 4 paliperidone ER
38 Efficacy and Safety With Ziprasidone in the Treatment of First-episode Schizophrenia Spectrum Disorder: Multi-center Study Completed NCT01157559 Phase 4 Ziprasidone
39 Efficacy and Safety of Aripiprazole in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study Completed NCT01026584 Phase 4 Aripiprazole
40 Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD) Completed NCT01178671 Phase 4 Mirtazapine;Sertraline
41 Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness Completed NCT03069482 Phase 4 Nicotine patch;Nicotine lozenge
42 Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
43 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year Completed NCT02534363 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
44 Post-marketing Clinical Study on PAXIL Tablet in Patients With Depression or Depressive Mood - A Study on Combination of PAXIL Tablet and Benzodiazepines Completed NCT00259883 Phase 4 paroxetine
45 An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease Completed NCT00095810 Phase 4 aripiprazole
46 The Cognitive Effects of Risperidone and Olanzapine Completed NCT00108368 Phase 4 Risperidone;Olanzapine
47 A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
48 Antidepressant Treatment at an Inner City Asthma Clinic Completed NCT01324700 Phase 4 High severity group: Escitalopram;High severity group: Placebo;Low severity group: Escitalopram;Low severity group: Placebo
49 An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis Completed NCT00644800 Phase 4 Ziprasidone
50 A Twelve-Week, Open, Randomized Trial Comparing Valproate to Lithium in Bipolar I Patients Suffering From a Manic Episode Completed NCT00264173 Phase 4 Valproate sodium

Search NIH Clinical Center for Disease of Mental Health

Cochrane evidence based reviews: mental disorders

Genetic Tests for Disease of Mental Health

Anatomical Context for Disease of Mental Health

MalaCards organs/tissues related to Disease of Mental Health:

41
Brain, Testes, Heart, Breast, Eye, Lung, Prostate

Publications for Disease of Mental Health

Articles related to Disease of Mental Health:

(show top 50) (show all 30002)
# Title Authors PMID Year
1
Update on Mental Health Aspects of Intimate Partner Violence. 38 17
31078204 2019
2
Effectiveness of a tailored implementation strategy to improve adherence to a guideline on mental health problems in occupational health care. 17
31053125 2019
3
The association between occupational stress and psychosomatic wellbeing among Chinese nurses: A cross-sectional survey. 17
31145327 2019
4
European mental health research resources: Picture and recommendations of the ROAMER project. 38
30579654 2019
5
Mental health services in the Northwest Territories: a scoping review. 38
31219779 2019
6
Vocational support in mental health service delivery in Australia. 38
30301392 2019
7
Mental health among Sami people with intellectual disabilities. 38
30664403 2019
8
Adverse childhood experiences, mental health, substance use, and HIV-related outcomes among persons with HIV. 38
30887831 2019
9
Associations between social jetlag and mental health in young people: A systematic review. 38
31387413 2019
10
Culture and Context in Mental Health Diagnosing: Scrutinizing the DSM-5 Revision. 38
29282590 2019
11
Parents' Spontaneous Attributions about their Problem Child: Associations with Parental Mental Health and Child Conduct Problems. 38
30929181 2019
12
Sexual Safety for In-Patient Mental Health Care-The Democratic Diagnosis of Change. 38
31180260 2019
13
Gender Minority Mental Health in the U.S.: Results of a National Survey on College Campuses. 38
31427032 2019
14
Strategies and Barriers in Addressing Mental Health and Suicidality in Patients With Cancer. 38
31424452 2019
15
Integrated Mind/Body Care in Women's Health: A Focus on Well-Being, Mental Health, and Relationships. 38
31378289 2019
16
Relation of positive memory recall count and accessibility with post-trauma mental health. 38
31189410 2019
17
Improving the mental health of Roma through research and policies that cross multiple social sectors. 38
31143962 2019
18
Therapist and Youth Predictors of Specific Practices Derived from the Evidence-Base in Community Mental Health. 38
31152274 2019
19
Current Status of Mental Health Services at the Primary Healthcare Level in Northern Nigeria. 38
31267243 2019
20
Implementation of a Mental Health Screening Program in a Pediatric Tertiary Care Setting. 38
31303026 2019
21
Mental health and primary dysmenorrhea: a systematic review. 38
29745745 2019
22
Neighbourhood ethnic diversity and mental health in Australia. 38
31290216 2019
23
Rapid Growth of Mental Health Services at Community Health Centers. 38
31273479 2019
24
Physical and mental health problems of self-employed small business owners in South Korea. 38
31328810 2019
25
Women's Auto/Biography and Dissociative Identity Disorder: Implications for Mental Health Practice. 38
28875484 2019
26
Parent Mental Health Problems and Motivation as Predictors of Their Engagement in Community-Based Child Mental Health Services. 38
31258235 2019
27
Cultural engagement and mental health: Does socio-economic status explain the association? 38
31336219 2019
28
Numeracy Skills and Self-Reported Mental Health in People Aging Well. 38
31222690 2019
29
Depressive disorders, anxiety disorders and subjective mental health in common musculoskeletal diseases: A review. 38
31351516 2019
30
Improving Mental Health for the Mother-Infant Dyad by Nutrition and the Maternal Gut Microbiome. 38
31383280 2019
31
Hispanics, Mental Health, and Suicide: Brief Report. 38
30991838 2019
32
Resident Mental Health: Time for Action. 38
31299659 2019
33
Mental health status and dietary intake among California adults: a population-based survey. 38
30773065 2019
34
"How Can We Help You": Mental Health Practitioners' Experiences of Service Provision in Northern Namibia. 38
31079350 2019
35
Parenting time, parenting quality, interparental conflict, and mental health problems of children in high-conflict divorce. 38
31318261 2019
36
Mizen, Richard. (2019). 'The affective basis of violence'. Infant Mental Health Journal, 2019, 1-14. 38
31418845 2019
37
Building Mental Health Research Capacity in Kenya: A South - North Collaboration. 38
31403024 2019
38
Vigorous physical activity and mental health-Associations suggest a link among childhood cancer survivors. 38
31067354 2019
39
Postnatal mental health and mothers' processing of infant emotion: an eye-tracking study. 38
31117817 2019
40
Mental health stigma among people of color: An examination of the impact of racial discrimination. 38
31234686 2019
41
Pathways to mental health treatment in Ghana: Challenging biomedical methods from herbal- and faith-healing perspectives. 38
31277557 2019
42
Availability, readability, and content of privacy policies and terms of agreements of mental health apps. 38
30949436 2019
43
Effects of society and culture on parents' ratings of children's mental health problems in 45 societies. 38
30659384 2019
44
Adverse childhood experiences, childhood relationships and associated substance use and mental health in young Europeans. 38
30897194 2019
45
Veterans Health Administration Investments In Primary Care And Mental Health Integration Improved Care Access. 38
31381382 2019
46
Exploring a model for infant and early childhood mental health consultation in early childhood home visiting. 38
31385335 2019
47
Mental Health, Help-Seeking Behaviour and Social Support in the UK Armed Forces by Gender. 38
31385751 2019
48
Mothers' Mental Health Care Use After Screening for Postpartum Depression at Well-Child Visits. 38
30496869 2019
49
Associations of Suicide Prevention Trainings with Practices and Confidence among Clinicians at Community Mental Health Centers. 38
30073698 2019
50
Prevalence of mental disorders and mental health service use in Japan. 38
31141260 2019

Variations for Disease of Mental Health

ClinVar genetic disease variations for Disease of Mental Health:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 LOC730100 NC_000002.10: g.51151955_51190352del38398 deletion no interpretation for the single variant 2:51298451-51336848 2:51071313-51109710
2 LOC730100 NC_000002.10: g.51440969_51481281del40313 deletion no interpretation for the single variant 2:51587465-51627777 2:51360327-51400639

Expression for Disease of Mental Health

Search GEO for disease gene expression data for Disease of Mental Health.

Pathways for Disease of Mental Health

Pathways related to Disease of Mental Health according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 SLC6A3 OPRM1 DRD4 DRD3 DRD2 COMT
2
Show member pathways
12.53 MAPT DRD4 DRD3 DRD2 BDNF
4 11.76 SLC6A4 MECP2 HTR2A HTR1A BDNF
5 11.76 OPRM1 MECP2 MAPT HTR1A HCRT FMR1
6
Show member pathways
11.75 SLC6A3 DRD2 BDNF
7 11.73 SLC6A4 HTR2A HTR1A
8
Show member pathways
11.66 DRD4 DRD3 DRD2
9 11.64 HTR2A DRD4 DRD3
10
Show member pathways
11.4 HTR2A HTR1A DRD4 DRD3 DRD2
11 10.94 SLC6A4 HTR2A HTR1A
12
Show member pathways
10.85 SLC6A4 SLC6A3 COMT

GO Terms for Disease of Mental Health

Cellular components related to Disease of Mental Health according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.88 SLC6A3 MAPT HTR2A FMR1 APOE
2 glutamatergic synapse GO:0098978 9.85 HTR2A DRD4 DRD3 DRD2 APOE
3 membrane raft GO:0045121 9.8 SLC6A4 SLC6A3 OPRM1 MAPT
4 dendritic spine GO:0043197 9.73 MAPT FMR1 DRD2 COMT
5 postsynapse GO:0098794 9.67 MECP2 HCRT FMR1 DRD4
6 integral component of presynaptic membrane GO:0099056 9.65 SLC6A4 SLC6A3 OPRM1 HTR2A DRD2
7 axon GO:0030424 9.56 SLC6A3 OPRM1 MAPT HTR2A FMR1 DRD2
8 integral component of postsynaptic membrane GO:0099055 9.55 SLC6A4 SLC6A3 OPRM1 HTR2A DRD2
9 glial cell projection GO:0097386 9.51 MAPT FMR1
10 dopaminergic synapse GO:0098691 9.5 SLC6A3 DRD3 DRD2
11 dendrite GO:0030425 9.32 OPRM1 MAPT HTR2A HTR1A FMR1 DRD4
12 plasma membrane GO:0005886 10.3 SLC6A4 SLC6A3 OPRM1 MAPT HTR2A HTR1A
13 integral component of plasma membrane GO:0005887 10.01 SLC6A4 SLC6A3 OPRM1 HTR2A HTR1A DRD4

Biological processes related to Disease of Mental Health according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 SLC6A4 SLC6A3 HTR2A DRD3 DRD2 COMT
2 response to ethanol GO:0045471 9.92 SLC6A3 OPRM1 DRD3 DRD2
3 cellular calcium ion homeostasis GO:0006874 9.89 HTR2A DRD4 DRD3 APOE
4 locomotory behavior GO:0007626 9.88 SLC6A3 OPRM1 DRD3 DRD2
5 learning GO:0007612 9.85 MECP2 DRD3 COMT
6 synapse assembly GO:0007416 9.85 MECP2 DRD2 BDNF
7 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.85 OPRM1 HTR2A HCRT
8 sensory perception of pain GO:0019233 9.85 OPRM1 MECP2 HTR2A
9 visual learning GO:0008542 9.84 MECP2 DRD3 DRD2
10 excitatory postsynaptic potential GO:0060079 9.84 OPRM1 MECP2 HCRT DRD2
11 response to amphetamine GO:0001975 9.82 DRD4 DRD3 DRD2
12 long-term memory GO:0007616 9.81 MECP2 DRD2 APOE
13 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.81 HTR2A HTR1A DRD4
14 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.81 OPRM1 HTR2A HTR1A DRD4
15 response to morphine GO:0043278 9.8 OPRM1 DRD3 DRD2
16 behavioral fear response GO:0001662 9.8 MECP2 HTR1A DRD4
17 social behavior GO:0035176 9.78 SLC6A4 MECP2 DRD4 DRD3
18 arachidonic acid secretion GO:0050482 9.76 DRD4 DRD3 DRD2
19 temperature homeostasis GO:0001659 9.74 HTR2A HCRT DRD2
20 negative regulation of protein secretion GO:0050709 9.73 DRD4 DRD3 DRD2
21 synaptic transmission, dopaminergic GO:0001963 9.72 DRD3 DRD2
22 response to iron ion GO:0010039 9.72 SLC6A3 DRD2
23 dopamine receptor signaling pathway GO:0007212 9.72 DRD4 DRD3 DRD2
24 vasoconstriction GO:0042310 9.71 SLC6A4 HTR1A
25 startle response GO:0001964 9.71 MECP2 DRD2
26 positive regulation of renal sodium excretion GO:0035815 9.71 DRD3 DRD2
27 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A4 SLC6A3
28 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.71 DRD4 DRD3
29 G protein-coupled receptor internalization GO:0002031 9.7 DRD3 DRD2
30 negative regulation of potassium ion transport GO:0043267 9.7 HTR2A HCRT
31 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.7 OPRM1 DRD3
32 serotonin receptor signaling pathway GO:0007210 9.7 HTR2A HTR1A
33 prepulse inhibition GO:0060134 9.7 SLC6A3 DRD3 DRD2
34 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.69 HTR2A DRD2
35 monoamine transport GO:0015844 9.69 SLC6A4 SLC6A3
36 behavior GO:0007610 9.69 HTR2A HTR1A
37 adenohypophysis development GO:0021984 9.68 SLC6A3 DRD2
38 dopamine catabolic process GO:0042420 9.68 SLC6A3 COMT
39 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.66 DRD3 DRD2
40 negative regulation of dopamine receptor signaling pathway GO:0060160 9.66 DRD3 DRD2
41 regulation of locomotion involved in locomotory behavior GO:0090325 9.65 DRD3 DRD2
42 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.65 DRD4 DRD2
43 acid secretion GO:0046717 9.65 DRD3 DRD2
44 memory GO:0007613 9.65 SLC6A4 MECP2 MAPT HTR2A BDNF
45 regulation of dopamine metabolic process GO:0042053 9.63 SLC6A3 HTR1A DRD4
46 response to cocaine GO:0042220 9.62 SLC6A3 OPRM1 DRD3 DRD2
47 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD4 DRD3 DRD2
48 neurological system process involved in regulation of systemic arterial blood pressure GO:0001976 9.6 MECP2 DRD2
49 negative regulation of voltage-gated calcium channel activity GO:1901386 9.58 FMR1 DRD4 DRD2
50 behavioral response to ethanol GO:0048149 9.54 OPRM1 DRD4 DRD2

Molecular functions related to Disease of Mental Health according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.95 OPRM1 HTR2A HTR1A DRD4 DRD3 DRD2
2 neurotransmitter receptor activity GO:0030594 9.58 HTR2A HTR1A DRD4
3 G protein-coupled serotonin receptor activity GO:0004993 9.54 HTR2A HTR1A DRD4
4 adrenergic receptor activity GO:0004935 9.52 DRD3 DRD2
5 neurotransmitter:sodium symporter activity GO:0005328 9.51 SLC6A4 SLC6A3
6 serotonin binding GO:0051378 9.5 SLC6A4 HTR2A HTR1A
7 siRNA binding GO:0035197 9.49 MECP2 FMR1
8 monoamine transmembrane transporter activity GO:0008504 9.46 SLC6A4 SLC6A3
9 lipoprotein particle binding GO:0071813 9.43 MAPT APOE
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD4 DRD3 DRD2
11 drug binding GO:0008144 9.35 SLC6A3 HTR2A DRD4 DRD3 DRD2
12 dopamine neurotransmitter receptor activity GO:0004952 9.33 DRD4 DRD3 DRD2
13 dopamine binding GO:0035240 8.92 SLC6A3 DRD4 DRD3 DRD2

Sources for Disease of Mental Health

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....